Moneycontrol PRO
Live Now |Super25 3.0- India’s Largest Online Stock Traders Conference brought to you by Moneycontrol Pro & Espresso
you are here: HomeNewsBusiness

USFDA issues 3 minor observations to Granules India arm in pre-approval inspection

Granules Pharmaceuticals located in Chantilly, Virginia, US, had undergone a PAI by the US Food and Drug Administration (USFDA) from January 24-28, 2022, the company said in a statement.

January 31, 2022 / 01:42 PM IST

Drug firm Granules India Ltd on Monday said the US health regulator US Food and Drug Administration (USFDA) has issued "three minor observations" to its wholly-owned arm Granules Pharmaceuticals, Inc (GPI) in a pre-approval inspection (PAI).


Granules Pharmaceuticals located in Chantilly, Virginia, US, had undergone a PAI by the US Food and Drug Administration (USFDA) from January 24-28, 2022, the company said in a statement.

"The audit is a PAI for two of its product applications filed from this facility. The USFDA issued three minor observations during the audit conducted at the facility," it added, without elaborating on the nature of the observations. Commenting on the audit, GPI Executive Director Priyanka Chigurupati said, "We are glad to have completed yet another audit with minor observations that we will respond to within the stipulated time period".



Download your money calendar for 2022-23 here and keep your dates with your moneybox, investments, taxes

PTI
first published: Jan 31, 2022 01:42 pm
Sections
ISO 27001 - BSI Assurance Mark